Since Congress passed the 21st Century Cures Act on July 10th, one Big Pharma company has already moved to capitalize on the legislation even before it has been passed by the Senate and become law. A good introduction to the bill can be found in this piece. In short, the bill is designed to speed up the route to market for certain therapeutics. Senate passage is estimated for around December. In the last piece I paid particular attention to one of the most consequential aspects of the Act - that it would promote the development of brand-new antibiotics. In response to the Act, there have been two interpretations of this likely influx of therapeutics.